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Economic evaluation of arthritis selfmanagement in primary
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Anita Patel, senior lecturer,1 Marta Buszewicz, senior lecturer,2 Jennifer Beecham, principal research fellow,3
professor of health and social care economics,4 Mark Griffin, lecturer,2 Greta Rait, senior clinical lecturer,2,5
Irwin Nazareth, professor,2,5 Angela Atkinson, clinical trial officer,6 Julie Barlow, professor of health
psychology, research director,7 Andy Haines, director, professor of public health and primary care8
ABSTRACT
Objective To assess the cost effectiveness of a self
management programme plus education booklet for
arthritis in primary care.
Design Cost effectiveness and cost utility analysis from
health and social care and societal perspectives
alongside a randomised controlled trial.
Setting 74 general practices in the United Kingdom.
Participants 812 patients aged 50 or more with
osteoarthritis of the hips or knees, or both, and pain or
disability, or both.
Interventions Randomisation to either six sessions of an
arthritis self management programme plus an education
booklet (intervention group) or the education booklet
alone (standard care control group).
Main outcome measures Total health and social care
costs and total societal costs at 12 months; cost
effectiveness (incremental cost effectiveness ratios and
cost effectiveness acceptability curves) on basis of
quality of life (SF-36, primary outcomemeasure), EuroQol
visual analogue scale, and quality adjusted life years
(QALYs).
Results At 12 months health and social care costs in the
intervention group were £101 higher (95% confidence
interval £3 to £176) than those in the control group
because the additional costs of the arthritis self
management programme did not seem to be fully offset
by savings elsewhere. There were no significant
differences in societal costs (which were up to 13 times
the size of health and social care costs) or any of the
outcomes. From the health and social care perspective
the intervention was dominated by the control on the
basis of QALYs (which were non-significantly lower in the
intervention group) and had incremental cost
effectiveness ratios between £279 and £13473 for the
other outcomes. From the societal perspective the
intervention seemed superior to the control owing to non-
significantly lower costs and non-significantly better
outcomes on all measures except QALYs. Probabilities of
the arthritis self management programme’s cost
effectiveness ranged between 12% and 97% (for
thresholds ranging £0 to £1000) based on one point
improvements in SF-36 outcomes, but the clinical
significance of this is debatable. Probabilities of cost
effectiveness on the basis of the visual analogue scale
and QALYs were low.
Conclusions Cost effectiveness of an arthritis self
management programme is not suggested on the basis of
current National Institute for Health and Clinical
Excellence cost perspectives and QALY thresholds. The
probability of cost effectiveness is greater when broader
costs and other quality of life outcomes are considered.
These results suggest that the cost effectiveness of the
Department of Health’s expert patients programme
cannot be assumed across all clinical conditions and that
further rigorous evaluations for other conditions may be
needed.
Trial registration Current Controlled Trials
ISRCTN79115352.
INTRODUCTION
Osteoarthritis is one of the most common forms of
arthritis, with at least 4.4 million people in the United
Kingdom experiencing moderate or severe disease.1
Arthritis is one of the biggest causes of disability, cost-
ing the National Health Service and social services
around £5.5bn ($9.1bn; €6.2bn) per annum and lead-
ing to 206 million lost working days in 1999-2000.2
The condition is the second most common cause for
days off work. An ageing population and longer work-
ing lives are likely to lead to increases in these societal
impacts.
Evaluations of arthritis self management pro-
grammes in the United States suggest that these rela-
tively inexpensive interventions can lead to a range of
patient centred benefits and reductions in healthcare
use. Although such studies provided the initial evi-
dence base for England’s expert patients programme,
they provided limited evidence of cost effectiveness
and had important methodological weaknesses.3 4
We assessed the cost effectiveness of a self manage-
ment programme for arthritis compared with usual
care within a large randomised trial based in UK pri-
mary care, using high quality and rigorous methodol-
ogies that would give meaningful results for both
clinicians and health policy planners.
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METHODS
Full details of the study have been described
elsewhere.5 Briefly, 812 patients aged 50 or more and
with osteoarthritis of the hips, knees, or both, and pain
or disability, or both, were recruited from 74 primary
care practices across the UK. The patients were rando-
mised to receive either six sessions of an arthritis self
management programme plus an education booklet
(intervention group) or the education booklet alone
(control group). The self management programme
was based on an existing course (ChallengingArthritis)
provided by the voluntary organisationArthritis Care.
The booklet was designed for the study and incorpo-
rated information available to the public fromArthritis
Care and the Arthritis Research Campaign. This
reflects standard primary care, where giving written
information is common practice.
The economic evaluation was undertaken from two
perspectives: health and social care and societal. It
focused on longer term cost effectiveness at the
12 month follow-up, although mean costs and out-
comes at four months are also reported. Although the
arthritis self management programme in this trial was
provided outside the health and social care sector, we
included it as a healthcare cost because theNHS is cur-
rently funding the implementation of such inter
ventions.6
Data collection
An adapted version of the client service receipt inven-
tory was used to collect economic data at individual
level,7 8 administered as a self completion question-
naire alongside the other outcome measures at the
baseline assessment before randomisation (in the gen-
eral practice) and at the four month and 12 month fol-
low-up (both by post). It focused on arthritis related
resource use for the previous three months and, along-
side personal characteristics, covered income and
employment status; use of health and social care
resources (drugs and hospital and community based
health and social care); costs borne by participants,
their family, and friends (out of pocket expenses, lost
pay, and informal care); indirect impacts (time offwork
for participants and carers); and receipt of social secur-
ity benefits.
Unit costs
To obtain three month costs for each participant at
each assessment point we applied unit costs (see web
extra on bmj.com) to data on resource use at individual
level as recorded on the client service receipt inven-
tory.Weused estimates for national unit costs to reflect
the fact that the study samplewas drawn frompractices
around the UK and to facilitate generalisation of the
findings.
Weestimated theunit cost of the arthritis selfmanage-
ment programme as an average cost per patient using a
top-down approach in the absence of detailed informa-
tion on the resources and costs absorbed by the pro-
gramme. This estimate was based on rates paid by the
trial to Arthritis Care for running the courses. Of 406
participants in the intervention group, seven could not
be found places on a course in their area. For the 399
offered a place, £65 780 was paid to Arthritis Care; an
average cost of £164.86 per participant. This cost cov-
ered the course of six sessions, regardless of how many
sessionswere attended.Wedescribe sensitivity analyses
to explore the potential implications of this costing
approach.The educationbooklet reflects standardprac-
tice in primary care and we assumed its costs to be
included within our cost estimates for primary care.
Costs are reported in pounds sterling and are standar-
dised to 2002-3 rates (the most recent available set of
unit costs after the study ended) using, as appropriate,
the NHS Executive’s hospital and community health
services inflation index or the personal social services
inflation index.9 Approximations of 2007-8 rates can
be made by multiplying costs by 1.2 (the inflation rate
for hospital and community health services pay and
prices9). It was not necessary to discount costs or out-
comes as the evaluation covered only one year.
Outcomes
The primary outcomes were the summary scores for
the physical and mental health components of the
short form health survey (SF-36).10 For the economic
evaluation we also included the visual analogue scale
and the five dimensional health state description of the
EuroQol, the EQ-5D.11 All outcome measures were
administered as self completion questionnaires during
attendance for the baseline assessment and by post at
the four and 12 month follow-ups. We applied utility
weights from a UK general population survey12 to the
EQ-5Dhealth states to calculate utility values andqual-
ity adjusted life years (QALYs). QALYs were calcu-
lated using the total area under the curve approach,
with linear interpolation between assessment points
and baseline adjustment for comparisons.13 To calcu-
late total QALYs for the one year follow-up period we
summed the QALYs at four months (representing the
period between the baseline and four month assess-
ment) and at 12 months (representing the period
between the four month and 12 month assessment).
Analyses
Data were double entered and analysed using SPSS for
Windows Release 11.0.1 and Stata 8.2 for Windows.
Data on resource use from the client service receipt
inventory formed the basis of the total cost calculation
for each participant. If no report existed on the use of a
particular resource on returned inventories, we
assumed that it was not used. If participants reported
on a resource but not the quantity used, we imputed
this from within group means for participants with
data for that item at the same assessment point. After
this imputation for specific missing items we carried
out inventory related analyses on available cases—
that is, we excluded those with completely missing
inventory data. Similarly, all five components of the
EQ-5D are required to compute utilities and QALYs
RESEARCH
page 2 of 9 BMJ | ONLINE FIRST | bmj.com
used in the economic evaluation. We imputed missing
EQ-5D components (where up to four of the five pos-
sible dimensions were missing) for seven of 630 (1.1%)
cases at four months and seven of 599 (1.2%) cases at
12months using the last value carried forwardmethod
because integers are needed in the application of utility
weights. We then carried out EQ-5D related analyses
on available cases after this imputation.
Health and social care costs included the costs of
health care, social care, and drugs. Societal costs were
calculated as these health and social care costs plus the
costs of informal care, social security benefit receipts,
and out of pocket expenses of participants and their
families and friends, lost pay, and time off work.
Costs and outcomes are reported as mean values
with standard deviations. Mean differences between
groups and 95% confidence intervals were obtained
by bootstrap regressions (5000 replications). The base-
line value of the relevant itemwas added as a covariate
for all comparisons of costs and outcomes at four and
12 months.
Weassessed cost effectiveness using cost effectiveness
acceptability curves. For each participant we calculated
the netmonetary benefit for a range ofmonetary values
and presented the bootstrapped data graphically.14 The
resulting curves show theprobability of the intervention
being cost effective comparedwith standard care for the
selected range of monetary values. We calculated cost
effectiveness acceptability curves for each of the four
outcome measures from both cost perspectives. Incre-
mental cost effectiveness ratios are also reported where
both costs and outcomes were higher for either group.
For both approaches to assess cost effectiveness, we
extrapolated costs at the 12month follow-up (represent-
ing a retrospective three month period) to a one year
period (that is, multiplied by four) to match the period
reflected by the QALY data, under the assumption that
these economic impacts were constant over the assess-
ment period.
Sensitivity analyses
As the base case evaluation excluded cases without
outcome data for the relevant analysis we assessed
the impact of missing outcomes at four months and
12 months by imputing full samples. We did this by
using the same hot decking and multiple imputation
procedure (SOLAS ForMissingData Analysis version
3.2; Statistical Solutions) used elsewhere for the analy-
sis of main study outcomes.5
We also undertook eight one way sensitivity ana-
lyses to assess the impact of various cost assumptions
on the total health and social care and societal costs at
12 months. Firstly, we examined the impact of cost
data being missing by imputing total costs using the
hot decking procedure andmultiple imputation proce-
dure. We compared alternative cost effectiveness
ratios on the basis of these imputed full sample costs
and outcomes with the base case ratios.
Secondly, within the intervention group the base
case evaluation includes 129 (32%) participants who
failed to attend any session of the arthritis self manage-
ment programme and a further 58 (14%) who attended
only 1-3 sessions. Thus, nearly half did not receive a
clinically significant “dose,” defined as attending four
Table 1 | Resource use at four months (for previous three month period) by patients assigned to an arthritis self management programme plus education
booklet or the education booklet only (usual care, control)
Resource Unit
Intervention group Control group
Valid No Mean (SD) Valid No Mean (SD)
Hospital based services:
Admissions Nights 286 0.04 (0.5) 314 0.20 (1.5)
Outpatients Appointments 286 0.17 (0.6) 312 0.21 (0.6)
Accident and emergency Visits 286 0.02 (0.2) 314 0.03 (0.2)
Physiotherapy Visits 284 0.26 (1.0) 304 0.19 (1.0)
Occupational therapy Visits 288 0.07 (0.4) 319 0.03 (0.2)
Community based services:
General practitioner Surgery visits 278 0.90 (1.4) 292 0.94 (1.3)
General practitioner Home visits 289 0.02 (0.1) 323 0.04 (0.4)
General practitioner Telephone calls 288 0.08 (0.5) 319 0.10 (0.5)
Practice nurse Surgery visits 282 0.21 (0.7) 313 0.27 (0.9)
Practice nurse Telephone calls 293 0.03 (0.2) 321 0.01 (0.1)
Repeat prescription without general practitioner contact Requests 236 1.36 (1.8) 251 1.43 (1.5)
Meals on wheels Meals 292 0 324 0.28 (5.0)
Home help Visits 292 0.29 (3.6) 319 0.53 (5.2)
Social worker Visits 293 0.02 (0.2) 322 0.02 (0.2)
Social worker Telephone calls 292 0.01 (0.1) 323 0.07 (0.6)
Physiotherapist Home visits 293 0.03 (0.4) 319 0.04 (0.7)
Physiotherapist Surgery or clinic visits 281 0.29 (1.2) 297 0.26 (1.0)
Occupational therapist Home visits 290 0.01 (0.1) 321 0.02 (0.2)
Informal care:
Total care per average week Hours 294 5.80 (11.4) 327 7.1 (14.5)
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or more sessions.15 Therefore the second sensitivity
analysis was a per protocol analysis of costs based on
those who attended four or more sessions.
The final six sensitivity analyses dealt with the aver-
age price charged to the trial by Arthritis Care as the
unit cost of the arthritis self management programme.
This price may not reflect the true economic cost per
patient. For example, many of the activities of Arthritis
Care are carried out by volunteers and the cost of their
time is not included in the price. Moreover, the unit
cost did not account for the number of sessions
attended by each participant or the number present at
each session. To deal with the various factors that
would lead to an under-estimation or over-estimation,
we varied the cost of the self management programme
by 20%, 35%, and 50% both upwards and downwards.
RESULTS
Response rates for the client service receipt inventory
were 94% (n=765) at baseline, 77% (n=622) at four
months, and 73% (n=595) at 12 months and were
balanced between the intervention and control groups.
Corresponding response rates for the EQ-5D were
94% (n=766), 78% (n=630), and 74% (n=599), which
were also balanced between the groups.
Resource use
Evidence from the US on the purported economic
advantages of self management interventions is com-
monly restricted to general practitioner visits, outpati-
ent visits, and inpatient days.3 16 Utilisation rates for
these services did not differ between the groups at
baseline. At four months, general practitioner visits
and outpatient visits remained similar (table 1), but
fewer people in the intervention group (1.4% v 2.9%)
had an inpatient stay, resulting in lower average inpa-
tient days (table 1). A similar pattern was seen at
12 months (table 2). However, in both groups the
trend was towards a reduction in general practitioner
visits and an increase in outpatient visits compared
with baseline. Hours spent on informal care were simi-
lar at all assessment points.
Costs
Atbaseline, health and social care costs or societal costs
did not differ between the groups (table 3). At four
months the intervention group had significantly higher
costs frombothperspectives. This is likely tobe adirect
consequence of the arthritis self management pro-
gramme because when the costs of the programme
were excluded a cost saving occurred in health and
social care costs but no difference in societal costs.
Health and social care costs in the intervention
group at 12months were £101 higher (95% confidence
interval £3 to £176) than those in the control group.
When the cost of the self management programme
was reduced by between 20% and 50% in sensitivity
analyses this difference became non-significant. Socie-
tal costs at 12 months were numerically, but not statis-
tically, lower in the intervention group. This
conclusion remained unchanged in all sensitivity ana-
lyses.
Although previous economic evaluations of self
management interventions have focused on healthcare
Table 2 | Resource use at 12 months (for previous three month period) by patients assigned to an arthritis self management programme plus education
booklet or the education booklet only (usual care, control)
Resource Unit
Intervention group Control group
Valid No Mean (SD) Valid No Mean (SD)
Hospital based services:
Admissions Nights 275 0.11 (1.1) 301 0.52 (4.3)
Outpatients Appointments 273 0.28 (0.7) 300 0.26 (0.9)
Accident and emergency Visits 274 0.02 (0.2) 301 0.04 (0.2)
Physiotherapy Visits 263 0.29 (1.1) 283 0.18 (0.7)
Occupational therapy Visits 272 0.08 (0.6) 297 0.06 (0.5)
Community based services:
General practitioner Surgery visits 255 0.85 (1.2) 280 0.90 (1.5)
General practitioner Home visits 279 0.01 (0.1) 298 0.02 (0.2)
General practitioner Telephone calls 276 0.08 (0.4) 296 0.11 (0.5)
Practice nurse Surgery visits 268 0.19 (0.9) 290 0.20 (0.9)
Practice nurse Telephone calls 277 0.01 (0.1) 299 0.02 (0.2)
Repeat prescription without general practitioner contact Requests 223 1.46 (1.7) 245 1.62 (1.8)
Meals on wheels Meals 278 0.01 (0.2) 298 0
Home help Visits 277 0.85 (11.0) 295 0.57 (5.8)
Social worker Visits 278 0.03 (0.3) 297 0.05 (0.3)
Social worker Telephone calls 278 0.06 (0.5) 296 0.06 (0.5)
Physiotherapist Home visits 277 0.01 (0.1) 299 0.05 (0.5)
Physiotherapist Surgery or clinic visits 258 0.30 (1.4) 281 0.21 (0.9)
Occupational therapist Home visits 277 0.01 (0.1) 298 0.06 (0.5)
Informal care:
Total care per average week Hours 285 7.15 (12.9) 310 9.53 (19.5)
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costs, and often for a limited range of services, health-
care costs formed a small proportion of societal costs
(7% at baseline). The largest single cost was social
security benefits, at 44% of societal costs at baseline.
Although benefits are often seen as a transfer cost,
they represent high costs to the state. Costs borne by
participants and their family and friends absorbed 37-
46% of societal costs at each assessment point; mostly
informal care. Costs for lost productivity were mini-
mal, as most participants were not employed.
Table 3 | Costs (£, 2002-3, three month periods), in base case and sensitivity analysis scenarios
Variables
Intervention Control Intervention−control; mean
difference* (95% CI)Valid No Mean (SD) Valid No Mean (SD)
Arthritis self management programme 406 162 (21) 406 0 162 (−160 to −164)
Health and social care costs excluding self management programme:
Baseline 384 82 (136) 381 84 (138) −1 (−21 to 18)
4 months 295 84 (144) 327 115 (282) −33 (−69 to −0.1)
12 months 285 112 (240) 310 172 (717) −61 (−159 to 14)
Costs to patient, family, and friends:
Baseline 384 510 (1472) 381 537(1075) −26 (−199 to 171)
4 months 294 479 (1073) 327 453 (845) 22 (−119 to 163)
12 months 285 452 (731) 310 581(1094) −129 (−270 to 25)
Indirect costs†:
Baseline 384 13 (113) 381 43 (361) −30 (−70 to 2)
4 months 295 15 (148) 327 20 (228) 2 (−22 to 27)
12 months 285 48 (469) 310 35 (318) 22 (−45 to 95)
Social security benefits:
Baseline 384 490 (614) 381 510 (633) −19 (−108 to 66)
4 months 295 620 (690) 327 545(628) 74 (−17 to 160)
12 months 285 668 (609) 310 699 (783) −28 (−133 to 76)
Total costs, health and social care perspective:
Baseline 384 82 (136) 381 84 (138) −1 (−21 to 18)
4 months‡ 295 246 (146) 327 115 (282) 129 (93 to 162)
12 months‡ 285 274 (241) 310 172 (717) 101 (3 to 176)
Total costs, societal perspective:
Baseline 384 1096 (1648) 381 1173 (1509) −77 (−295 to 153)
4 months‡ 294 1360 (1459) 327 1133 (1291) 238 (55 to 434)
12 months‡ 285 1442 (1322) 310 1487 (1918) −26 (−277 to 229)
Sensitivity analyses on total health and social care cost at 12months‡:
Imputed full sample§ 406 259 (363) 406 183 (683) 77 (−2 to 155)
Per protocol analysis 185 272 (234) 310 172 (717) 101 (−1 to 178)
20% increase in ASMP cost 285 307 (242) 310 172 (717) 133 (35 to 208)
35% increase in ASMP cost 285 331 (242) 310 172 (717) 158 (59 to 233)
50% increase in ASMP cost 285 355 (243) 310 172 (717) 182 (84 to 257)
20% decrease in ASMP cost 285 242 (241) 310 172 (717) 69 (−30 to 144)
35% decrease in ASMP cost 285 218 (241) 310 172 (717) 44 (−54 to 119)
50% decrease in ASMP cost 285 193 (240) 310 172 (717) 20 (−78 to 95)
Sensitivity analyses on total societal cost at 12 months‡:
Imputed full sample§ 406 1456 (1398) 406 1494 (1851) −34 (−270 to 202)
Per protocol analysis 185 1421 (1319) 310 1487 (1918) −10 (−286 to 256)
20% increase in ASMP cost 285 1475 (1322) 310 1487 (1918) 6 (−244 to 261)
35% increase in ASMP cost 285 1499 (1322) 310 1487 (1918) 31 (−220 to 286)
50% increase in ASMP cost 285 1523 (1322) 310 1487 (1918) 55 (−195 to 310)
20% decrease in ASMP cost 285 1410 (1322) 310 1487 (1918) −58 (−309 to 197)
35% decrease in ASMP cost 285 1386 (1322) 310 1487 (1918) −83 (−333 to 173)
50% decrease in ASMP cost 285 1361 (1322) 310 1487 (1918) −107 (−358 to 149)
ASMP=arthritis self management programme.
*Except for imputed full sample data, mean differences and confidence intervals were calculated using bootstrap regressions (5000 replications) with baseline scores as covariates for all
values at four and 12 months.
†Time off work (participants and carers).
‡Includes cost of ASMP.
§Missing data imputed using hot decking and multiple imputation procedures. Differences in means are adjusted for any baseline differences in costs between groups using analysis of
covariance, with baseline cost as covariate. Confidence intervals were calculated using standard parametric techniques.
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Outcomes
At 12months no significant differenceswere shown for
the SF-36 summary scores, visual analogue scale, and
QALYs (table 4). Confidence intervals suggested that
the intervention group had marginally lower EQ-5D
scores at four months; this difference did not remain
in the imputed full sample analysis. Although there
were some variations in mean differences for other
outcomes computed using the available case and the
imputed full sample approaches, the overall inter-
pretation of results did not differ.
Cost effectiveness
The highest probabilities of cost effectiveness were for
the two SF-36 outcomes from the societal perspective,
forwhichprobabilitieswere high even at low thresholds
of willingness to pay for extra point gains (fig 1). From
the health and social care perspective, however, prob-
abilities of cost effectiveness on the basis of the mental
health component exceeded 50% (that is, the inter-
vention was more likely to the cost effective option)
only at willingness to pay levels of £300 or more per
point gain and did not exceed 50% for the physical
health component for the threshold range examined.
Probabilities of cost effectiveness on the basis of the
visual analogue scale did not exceed 41% from either
perspective for the threshold range examined. Probabil-
ities of cost effectivenessbasedonQALYswere low,not
exceeding 2% from the health and social care perspec-
tive even at thresholds of £30000 per QALY gain and
peaking at 20% from the societal perspective for the
threshold range examined (fig 2).
The meaningfulness of incremental cost effective-
ness ratios is unclear given the lack of statistically sig-
nificant differences for most combinations of costs and
outcomes. Incremental cost effectiveness ratios from
the health and social care perspective at 12 months
were £279 for the SF-36 mental health component,
Table 4 | Outcomes, in base case and sensitivity analysis scenarios
Scenarios
Intervention Control Adjusted difference in means (intervention−control)
Valid No Mean (SD) Valid No Mean (SD) Mean difference* (95% CI)
Imputed full sample†: mean
difference (95% CI)
SF-36 physical health summary score:
Baseline 316 25.59 (11) 317 25.35 (12) 0.24 (−1.56 to 2.03)
4 months 234 25.98 (12) 268 25.66 (13) 0.12 (−1.48 to 1.49) 0.22 (−1.50 to 1.94)
12 months 231 25.62 (12) 252 25.18 (12) 0.34 (−1.35 to 2.00) 0.33 (−1.31 to 1.98)
SF-36 mental health summary score:
Baseline 316 51.79 (11) 317 50.53 (10) 1.26 (−0.38 to 2.89)
4 months 234 51.40 (11) 268 50.14 (11) 0.34 (−1.25 to 1.92) 0.11 (−1.18 to 1.40)
12 months 231 52.28 (11) 252 50.32 (10) 1.45 (−0.17 to 3.04) 1.35 (−0.03 to 2.74)
EuroQol visual analogue scale:
Baseline 347 63.15 (17) 359 63.43 (17) −0.28 (−2.73 to 2.27)
4 months 269 64.41 (17) 303 63.16 (18) 1.32 (−1.01 to 3.66) 1.72 (−0.32 to 3.76)
12 months 242 63.62 (18) 273 62.36 (17) 0.03 (−2.34 to 2.40) 0.73 (−1.38 to 2.85)
EQ-5D utility score:
Baseline 381 0.570 (0.25) 375 0.535 (0.28) 0.03 (−0.00 to 0.07)
4 months 299 0.552 (0.28) 331 0.556 (0.27) −0.04 (−0.07 to −0.00) −0.03 (−0.06 to 0.01)
12 months 285 0.578 (0.25) 312 0.559 (0.27) −0.005 (−0.04 to 0.03) −0.006 (−0.04 to 0.03)
QALYs:
Baseline to 4 months 290 0.191 (0.08) 316 0.183 (0.08) −0.006 (−0.01 to −0.00) −0.003 (−0.01 to 0.00)
4-12 months 256 0.383 (0.15) 291 0.373 (0.16) −0.01 (−0.03 to 0.01) −0.007 (−0.03 to 0.01)
Total for 1 year 248 0.580 (0.22) 278 0.558 (0.23) −0.01 (−0.04 to 0.01) −0.01 (−0.04 to 0.01)
QALYs=quality adjusted life years.
*Based on available data, with no imputation for missing cases. Mean differences and confidence intervals were calculated using bootstrap regressions (5000 replications) with baseline
scores as covariates for all values at four and 12 months.
†Missing data imputed using hot decking and multiple imputation procedures. Differences in means are adjusted for any baseline differences in outcomes between groups using analysis of
covariance, with baseline score as covariate. Confidence intervals were calculated using standard parametric techniques.
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Fig 1 | Cost effectiveness acceptability curve of an arthritis self
management programme (ASMP) on SF-36 and visual
analogue scale (VAS) outcomes
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£1189 for the SF-36 physical health component, and
£13 473 for the visual analogue scale. On the basis of
these three outcomes, the intervention group domi-
nated the control group from the societal perspective
because of lower costs and better outcomes.
The QALY disadvantage to the intervention group,
combinedwith higher health and social care costs, sug-
gests that from the health and social care perspective
the standard care approach was superior to the inter-
vention. From the societal perspective, cost savings in
the intervention group would need to be traded off
against modest QALY losses, which would be a con-
tentious policy decision. Thus neither the cost effec-
tiveness acceptability curve nor incremental cost
effectiveness ratio approach suggests that the inter-
vention is cost effective compared with standard care
on the basis of QALYs.
The broad conclusions of the approach on the basis
of the incremental cost effectiveness ratio did not
changewith the use of imputed full sample data. Ratios
remained similar except that the additional cost per
point gain on the visual analogue scale from the health
and social care perspective fell from £13 473 to £419 as
a result of a notable increase in mean difference in
visual analogue scale score (0.03 v 0.73; see table 4).
DISCUSSION
A self management programme for arthritis plus an
education booklet in primary care led to a statistically
significant increase in health and social care costs but
no difference in societal costs or any of the measured
outcomes at 12 months.
Although the lack of statistical significance for some
differences in costs and outcomes could be deemed to
weaken the cost effectiveness evidence, the inference
approach has limitations.17 So it is nevertheless relevant
to explore the implications for cost effectiveness. Some
small advantages on the SF-36 outcomes translated into
low incremental cost effectiveness ratios from the health
and social care perspective and dominance from the
societal perspective, as well as reasonably good prob-
abilities of cost effectiveness for the intervention under
the cost effectiveness acceptability curve approach.
Findings on the basis of QALYs were less favourable,
however: the intervention was dominated by the con-
trol from the health and social care perspective and
involved a trade-off between slightly reduced QALYs
and cost savings from the societal perspective. The cost
effectiveness acceptability curve approach showed low
probabilities of cost effectiveness evenwhenhighvalues
were placed on QALY gains.
An important finding was the small proportion of
support costs falling to theNHSand social care sectors.
Three month costs for health and social care services
were around £80 at baseline. Other societal costs were
almost 13 times that, illustrating the breadth of the eco-
nomic impacts of arthritis outside of these sectors.
Furthermore, the probabilities of cost effectiveness
were generally higher from a societal perspective, indi-
cating that economic benefits of this intervention are
likely to be borne more by participants, their families,
and friends and other government sectors. To join up
with wider policy considerations, such as the role of
carers in the long term management of people with
chronic conditions,18 broad perspectives are needed
in economic evaluations of interventions such as self
management programmes for arthritis to assess their
impact on all stakeholders, despite the additional
methodological challenges that this brings.19
Strengths and limitations of the study
This comprehensive economic evaluation, set within a
randomised controlled trial, was based on individual
patient data and therefore deals with many of the lim-
itations associated with previous evidence. Further-
more, it fills an important evidence gap; its findings
are likely to have a wider application because the sam-
ple was recruited from across the UK and among
patients who routinely attend primary care rather
than participants who had specifically volunteered to
take part in the intervention.
The inclusion of social security benefits in the eva-
luation from a societal perspective may be contentious
because such costs are generally considered to be trans-
fer payments. However, social security benefits are an
important consideration in certain patient groups and
when the economic criterion of equity is to be consid-
ered alongside that of efficiency in resource
allocation.20 21 We thought that examining an inter-
vention for a condition mainly endured by older peo-
ple without accounting for such costs would miss an
important dimension to public sector financing and
decision making.
Some data from the client service receipt inventory
were incomplete. Missing responses in self completed
questionnaires are to be expected, and given the size
and geographical spread of the sample and the breadth
of the analytical perspective taken it would not have
been feasible to collect these data from alternative
sources. To make efficient use of the data provided,
however, we imputed missing components.
Themain limitationwas that wewere unable tomea-
sure accurately the costs of the arthritis self manage-
ment programme. A bottom-up cost estimation,
based in the setting where the programme is most
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Fig 2 |Cost effectiveness acceptability curve of an arthritis
self management programme (ASMP) on QALY gains
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likely to be delivered, especially if funded by health
services, is necessary to examine the true cost effective-
ness of the course. Ideally, costs under different set-up
scenarios and from different perspectives of funders
would also be examined.Wewere informed byArthri-
tis Care that the charge to primary care trusts in Eng-
land at the time of the study was £2500 per course,
occasionally discounted to £1850, and that the cost
did not include any profit element. Group sizes of 10-
12 were reported, suggesting costs between £154 and
£250 per participant. Our unit cost falls into the lower
end of this range and is likely to be an underestimate
because it did not cover factors such as failed courses
and development costs. Furthermore, it is likely that
implementation in the NHS would incur additional
resources to coordinate the courses. Indeed, the
Department of Health estimated the cost of its expert
patients programme to be £250 per patient.6 However,
a lower unit cost of £123 per participant has been
reported elsewhere.4 What all estimates have in com-
mon is that they are basedon throughput,which in turn
may affect costs and cost effectiveness, as suggested by
the finding from our sensitivity analyses that total
health and social care costs would be equivalent to,
rather than higher than, costs under a standard care
approach if the unit cost of the arthritis self manage-
ment programme fell by 20-50%.
Aside from inflationary increases in prices, it is pos-
sible that costs and outcomes have changed since the
completion of the trial owing to a range of other factors
—for example, policy changes related to health care,
social care, social security, and carers. However, as we
carried out a controlled evaluation with balanced
groups at baseline, we have no reason to believe that
any such changes would have had a differential impact
on the two groups. The findings should therefore con-
tinue to be relevant, particularly as osteoarthritis is a
prevalent long termcondition and there remains a gov-
ernment policy to include and expand the expert
patients programme through the NHS.
Comparison with previous studies
Although a US study based on a primary care popula-
tion reported no differences in clinical outcomes or use
of healthcare resources at four months when compar-
ing an arthritis self management programme with an
arthritis self management programme book,22 the cost
effectiveness of arthritis self management programmes
against usual care was unproved. For example, a study
that found cost savings and improvements in pain was
based on decision modelling rather than individual
patient data.23 Poor methodologies leading to a lack
of good quality evidence were highlighted in a review
of 10 studies offering education on arthritis self
management.24 The review found that only three stu-
dies reported fewer physician visits and lower health-
care costs, whereas the remainder did not measure
service use or costs.
Studies in other populations, however, have sug-
gested that self management programmes can be cost
effective. A well designed economic evaluation of the
English NHS expert patients programme, a self care
programme for people with a range of self defined
long term conditions, found small advantages in costs
(mean difference −£27) and QALYs (mean difference
0.02) compared with a waiting list control.6 25 It is
unclear why our study did not reach similar conclu-
sions, particularly as our intervention cost was lower
(£165 v £250), but differences in study design may
have been contributing factors. For example, the eva-
luation of the expert patients programme covered a
broader range of clinical conditions, recruited volun-
teers, and had no specific inclusion or exclusion cri-
teria, and so may have included participants with
greater capacity for benefit.
A longitudinal study in people with heart disease,
lung disease, stroke, or arthritis examined a self man-
agement programmebasedon the generic principles of
arthritis self management programmes and reported
improvements in health status and reductions in
healthcare costs at one and two years.16 Several factors
should be considered in interpreting this finding.
Firstly, the cost implications of the intervention were
not considered within the framework of a formal eco-
nomic evaluation on the basis of costs at individual
level but were instead based on extrapolations of aver-
age costs for particular services (for example, changes
in visits to the emergency room or doctor). Secondly,
some extrapolations were based on non-significant
changes in costs over time. Finally, total costs per
patient were not estimated, making it difficult to
gauge the intervention’s overall cost effectiveness.
Two other non-randomised studies of self manage-
ment programmes reported cost offsets, but again the
findings were based on extrapolations of study group
means for a selection of services used, and cost effec-
tiveness was not assessed.26 27 Similar concerns were
expressed in a recent review of evidence for self man-
agement across different diseases.3
Implications for policy
The outcome analysis showed statistically significant
improvements for anxiety and perceived self efficacy
to manage symptoms.5 This economic evaluation did
not show such advantages for quality of life outcomes
or costs. Following the current policymaking stance of
focusing on QALYs and health and social care costs,
the findings reported here suggest that the arthritis self
management programme intervention has a low prob-
ability of being cost effective. The intervention is more
likely to be cost effective if a societal perspective is
taken—one that includes the financial effects on
patients and their families and friends—or greater
value is placed on SF-36 outcomes than on QALYs.
However, it must be borne inmind that the advantages
to the intervention group on the SF-36 outcomes were
small and the cost effectiveness acceptability curves are
based on willingness to pay for one point advantages
on the SF-36. The clinical significance of such small
changes on the SF-36 is debatable.
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Conclusions and needs for future research
The conclusions from this study depend on perceptions
of the relative importance of health and social care and
societal costs and the appropriate outcomes for this
patient group. The study does not suggest cost effective-
ness based on the health and social care cost perspective
or implicit cost per QALY threshold currently used by
the National Institute for Health and Clinical Excel-
lence. However arthritis has broad impacts and we
found that there may be modest cost effectiveness
advantages for the arthritis self management pro-
gramme when other major impacts such as informal
care and social security benefits are taken into account
alongside small gains of doubtful clinical relevance on
the SF-36. Further rigorous appraisal of the cost effec-
tiveness of the Department of Health’s expert patients
programme is warranted for other meaningful health
outcomes and other clinical conditions.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Evaluations of arthritis self management programmes in the United States suggested that
these relatively inexpensive interventions can lead to a range of patient centred benefits and
reductions in healthcare use
Although such studies provided the initial evidence base for England’s expert patients
programme, they had narrow perspectives, methodological flaws, and uncertain applicability
to the UK
WHAT THIS STUDY ADDS
Cost effectiveness of arthritis self management programmes is not suggested on the basis of
current cost perspectives and QALY thresholds from the National Institute for Health and
Clinical Excellence
The probability of cost effectiveness is greater when broader costs and other quality of life
outcomes are considered
At 7% of societal costs, costs for health and social care constitute a small proportion of total
economic costs in this patient group
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